All In Biotech

Drug Trial Radar · NCT07227012

Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.

AN INTERVENTIONAL OPEN-LABEL PHASE 1B/2 STUDY TO EVALUATE SAFETY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF PF-08634404 AS MONOTHERAPY AND COMBINATION THERAPY IN ADULT PARTICIPANTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA

Last checked: Nov 20, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 138 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

138

Planned (sponsor's estimate)

Start

Dec 1, 2025

Primary completion

Oct 18, 2027

Study completion Oct 17, 2028

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Nov 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to learn about the effects of study medicine (PF-08634404) when given alone or with another antibody (ipilimumab) for the treatment of a type of liver cancer called hepatocellular carcinoma (HCC) that is either locally advanced (spread to nearby tissues) or has spread to other parts of the body. To join the study, participants must meet the following conditions: * Be 18 years or older. * Have locally advanced or metastatic HCC. * Is not a candidate for complete surgical or loco-regional therapies. * Have not received any whole-body treatment for HCC. Participants will receive PF-08634404 either alone or in combination with ipilimumab. The medicine will be given through intravenous (IV) infusions, which means it will be administered directly into a vein. All treatments will take place at clinical trial sites, where trained medical staff will monitor participants during and after each visit.

Conditions

  • Carcinoma, Hepatocellular
  • Hepatocellular Cancer
  • Hepatocellular Carcinoma
  • Unresectable Hepatocellular Carcinoma
  • Liver Neoplasms
  • Advanced Hepatocellular Carcinoma
  • Metastatic Hepatocellular Carcinoma

Interventions

  • PF-08634404Biological

    Solution for infusion

  • IpilimumabBiological

    Solution for infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse EventsTime frame: Through end of study and up to approximately 24 months
  2. Phase 1b: Number of participants with Dose limiting toxicities (DLT)Time frame: Through 90 days after the last dose of study intervention; Approximately 24 months
  3. Phase 2: Confirmed Overall Response Rate (ORR) using RECIST 1.1 as assessed by investigatorTime frame: Approximately 24 months
  4. Phase 2: Recommended dose of PF-08634404 in combination with ipilimumabTime frame: Approximately 24 months

Locations

60 sites in 5 countries. Site status is shown where the registry gives one.

  • Chao Family Comprehensive Cancer Center and Ambulatory Care

    Irvine, California · Recruiting

  • UCI Health - Irvine Infusion Pharmacy ACC

    Irvine, California · Recruiting

  • UCI Health - Irvine

    Irvine, California · Recruiting

  • START Los Angeles, LLC

    Los Angeles, California · Recruiting

  • Keck Hospital of USC

    Los Angeles, California · Recruiting

  • Los Angeles General Medical Center

    Los Angeles, California · Recruiting

  • USC/Norris Comprehensive Cancer Center / Investigational Drug Services

    Los Angeles, California · Recruiting

  • USC/Norris Comprehensive Cancer Center

    Los Angeles, California · Recruiting

  • LACN Century City

    Los Angeles, California · Recruiting

  • UC Irvine Health - Chao Family Comprehensive Cancer Center

    Orange, California · Recruiting

  • Keck Medical Center of USC Pasadena

    Pasadena, California · Recruiting

  • Moffitt Cancer Center at Speros

    Land O' Lakes, Florida · Recruiting

  • Moffitt Cancer Center at SouthShore

    Ruskin, Florida · Recruiting

  • Moffitt Cancer Center - International Plaza

    Tampa, Florida · Recruiting

  • Moffitt Cancer Center - McKinley Campus

    Tampa, Florida · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • Moffitt McKinley Hospital

    Tampa, Florida · Recruiting

  • Moffitt Cancer Center at Wesley Chapel

    Wesley Chapel, Florida · Recruiting

  • Memorial Hospital

    Shiloh, Illinois · Recruiting

  • Siteman Cancer Center - Shiloh

    Shiloh, Illinois · Recruiting

  • Allina Health Cancer Institute - Mercy Hospital

    Coon Rapids, Minnesota · Recruiting

  • Allina Health Cancer Institute - Abbott Northwestern Hospital

    Minneapolis, Minnesota · Recruiting

  • Allina Health Cancer Institute - United Hospital

    Saint Paul, Minnesota · Recruiting

  • Siteman Cancer Center - St. Peters

    City of Saint Peters, Missouri · Recruiting

  • Siteman Cancer Center - West County

    Creve Coeur, Missouri · Recruiting

  • Siteman Cancer Center - North County

    Florissant, Missouri · Recruiting

  • Saint Luke's Cancer Institute

    Kansas City, Missouri · Recruiting

  • Saint Luke's Hospital of Kansas City

    Kansas City, Missouri · Recruiting

  • Siteman Cancer Center

    St Louis, Missouri · Recruiting

  • Barnes-Jewish Hospital

    St Louis, Missouri · Recruiting

  • Washington University School of Medicine - Siteman Cancer Center

    St Louis, Missouri · Recruiting

  • Siteman Cancer Center - South County

    St Louis, Missouri · Recruiting

  • Renown Health Medical Oncology

    Reno, Nevada · Recruiting

  • Renown Office of Clinical Research

    Reno, Nevada · Recruiting

  • Renown Regional Medical Center

    Reno, Nevada · Recruiting

  • Duke Cancer Center Cary

    Cary, North Carolina · Recruiting

  • Duke Cancer Center - Investigational Chemotherapy Service

    Durham, North Carolina · Recruiting

  • Duke Cancer Center

    Durham, North Carolina · Recruiting

  • Duke University - Main Hospital and Clinics

    Durham, North Carolina · Recruiting

  • Duke Cancer Center Raleigh

    Raleigh, North Carolina · Recruiting

Showing 40 of 60 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.